abbv-151
mAbexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 21, 2019 (NCT03821935)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314989 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06632951 | Phase 2 | Dec 31, 2024 | AbbVie |
| NCT06487559 | Phase 1 | Sep 11, 2024 | AbbVie |
| NCT06236438 | Phase 2/Phase 3 (Phase 3) | Apr 10, 2024 | AbbVie |
| NCT06109272 | Phase 2/Phase 3 (Phase 3) | Jan 16, 2024 | AbbVie |
| NCT05822752 | Phase 2 | Sep 21, 2023 | AbbVie |
| NCT03821935 | Phase 1 | Feb 21, 2019 | AbbVie |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 6 | 6 | 3 | 2019 |
1 organizations
Page 1 / 1